<DOC>
	<DOCNO>NCT02535546</DOCNO>
	<brief_summary>Patients suffer chronic obstructive pulmonary disease ( COPD ) commonly get exacerbation illness many potential trigger include infection . The common cause lung infection/pneumonia organism name Streptococcus pneumoniae . In Ireland 13-valent pneumococcal conjugate vaccine ( PCV-13 ) recently introduce childhood vaccination programme . This study aim investigate carriage rate S. pneumoniae COPD patient one year determine isolate S. pneumoniae find within COPD population would cover PCV-13 vaccine .</brief_summary>
	<brief_title>Seasonal Trends Pneumococcal Carriage COPD Patients</brief_title>
	<detailed_description>This study aim determine potential contribution S. pneumoniae morbidity patient COPD Ireland PCV-13 potential reduce infective exacerbation cohort . A group 150 COPD patient monitor quarterly interval one year . At study visit patient report change COPD-related medication , recent hospitalisation exacerbation provide sputum sample ( pharyngeal swab possible ) assess presence S. pneumoniae . The specific objective study : 1 . To monitor carriage rate pneumococcus cohort Irish patient COPD outside period acute exacerbation one year period . 2 . To assess COPD exacerbation rate amongst group patient . 3 . To monitor change proportion patient positive pneumococci carriage full season document patient intermittently permanently colonise . 4 . To characterise S. pneumoniae isolates carry COPD patient term genetic evolution , comparison strain country , antimicrobial susceptibility . 5 . To assess proportion colonise COPD patient would cover current future pneumococcal vaccine .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Over 18 year age . Have clinical diagnosis COPD . Have force expiratory volume one second/forced vital capacity ( FEV1/FVC ) ratio &lt; 80 % . Patients unwell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Pneumococcal conjugate vaccine-13 ( PCV-13 )</keyword>
	<keyword>Pneumococcal polysaccharide vaccine-23 ( PPV-23 )</keyword>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>